Fast Market Research

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2017 - New Study

Fast Market Research announces the availability of the new Global Markets Direct report, "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017", on their comprehensive research portal

 

Boston, MA -- (SBWIRE) -- 06/21/2017 -- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Get More Details on this Report and a Full Table of Contents at Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 14, 10, 70, 31 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 23 and 22 molecules, respectively.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).

-The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)

Reasons to Get this Report

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Companies Mentioned in this Report: AbbVie Inc, Absynth Biologics Ltd, Actelion Ltd, Adenium Biotech ApS, Alchemia Ltd, Allergan Plc, AmpliPhi Biosciences Corp, Antibiotx ApS, Aphios Corp, Aridis Pharmaceuticals LLC, AstraZeneca Plc, Atriva Therapeutics GmbH, Bavarian Nordic A/S, Bharat Biotech International Ltd, C3J Therapeutics Inc, Cellceutix Corp, Cempra Inc, Citius Pharmaceuticals Inc, Common Pharma Inc, ContraFect Corp, Crestone Inc, Critical Outcome Technologies Inc, CrystalGenomics Inc, CytaCoat AB, Daiichi Sankyo Company Ltd, Debiopharm International SA, Dermala Inc, DesignMedix Inc, Destiny Pharma Ltd, Dong-A Socio Holdings Co Ltd, Emergent BioSolutions Inc, Ensol Biosciences Inc, Galapagos NV, GangaGen Inc, Helix BioMedix Inc, Hsiri Therapeutics LLC, Ildong Pharmaceutical Co Ltd, Immupharma Plc, iNtRON Biotechnology Inc, ioGenetics Inc, Kyorin Pharmaceutical Co Ltd, Lead Discovery Center GmbH, LegoChem Biosciences Inc, Lipocure Ltd, Madam Therapeutics BV, Melinta Therapeutics Inc, Merck & Co Inc, Microbiotix Inc, MicuRx Pharmaceuticals Inc, MorphoSys AG, Motif Bio Plc, Nabriva Therapeutics AG, Nemus Bioscience Inc, Novabiotics Ltd, NovaDigm Therapeutics Inc, Novalex Therapeutics Inc, NovoBiotic Pharmaceuticals LLC, Oragenics Inc, Ovensa Inc, Pfizer Inc, Phico Therapeutics Ltd, Prommune Inc, Recce Ltd, Savara Inc, Sealife PHARMA GMBH, Soligenix Inc, Sorrento Therapeutics Inc, Taejoon Pharm Co Ltd, TAXIS Pharmaceuticals Inc, Telephus Medical LLC, Tetraphase Pharmaceuticals Inc, Theravance Biopharma Inc, Trellis Bioscience Inc, Valevia UK Ltd, VLP Biotech Inc, Wockhardt Ltd, XBiotech Inc, Yungjin Pharm Co Ltd

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:
-Ulcerative Colitis - Pipeline Review, H1 2017
-Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016
-Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016
-Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2017
-Clostridium difficile Infections - Pipeline Review, H1 2017